MedTrace Logo

Physical Function During ARSI Treatment

NCT05612880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2025-01-09

No results posted yet for this study

Summary

This single arm observational pilot study aims to determine the longitudinal effects of androgen receptor signaling inhibitors (ARSI) in men with advanced prostate cancer. The primary outcome for this trial is physical function, which will be evaluated at baseline, 12 and 24 weeks. Secondary outcomes including body composition, muscle function, balance, arterial stiffness and patient reported outcomes.

Conditions

  • Advanced Prostate Carcinoma

Interventions

DRUG

androgen receptor signaling inhibitors

Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Erik D Hanson, PhD · UNC-Chapel Hill

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-13
Primary Completion
2024-11-06
Completion
2024-11-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612880 on ClinicalTrials.gov